10,000 Shares in Iovance Biotherapeutics, Inc. (NASDAQ:IOVA) Acquired by One68 Global Capital LLC

One68 Global Capital LLC acquired a new stake in shares of Iovance Biotherapeutics, Inc. (NASDAQ:IOVA) during the fourth quarter, according to the company in its most recent filing with the Securities & Exchange Commission. The firm acquired 10,000 shares of the biotechnology company’s stock, valued at approximately $74,000.

A number of other institutional investors have also made changes to their positions in IOVA. AlphaQuest LLC lifted its holdings in Iovance Biotherapeutics by 63.6% in the 4th quarter. AlphaQuest LLC now owns 4,613 shares of the biotechnology company’s stock worth $34,000 after buying an additional 1,794 shares in the last quarter. SBI Securities Co. Ltd. bought a new position in Iovance Biotherapeutics in the 4th quarter worth about $36,000. Quarry LP bought a new position in Iovance Biotherapeutics in the 4th quarter worth about $74,000. Integrity Wealth Advisors Inc. bought a new position in Iovance Biotherapeutics in the 4th quarter worth about $77,000. Finally, Jump Financial LLC bought a new position in shares of Iovance Biotherapeutics in the fourth quarter valued at approximately $79,000. 77.03% of the stock is owned by institutional investors and hedge funds.

Analysts Set New Price Targets

Several analysts recently commented on IOVA shares. Piper Sandler cut their target price on shares of Iovance Biotherapeutics from $7.50 to $6.00 and set a “neutral” rating for the company in a research note on Friday, February 28th. HC Wainwright reiterated a “buy” rating and set a $32.00 price target on shares of Iovance Biotherapeutics in a report on Friday, February 28th. The Goldman Sachs Group reduced their price objective on Iovance Biotherapeutics from $18.00 to $16.00 and set a “buy” rating for the company in a research report on Thursday, April 17th. Robert W. Baird reduced their price objective on Iovance Biotherapeutics from $24.00 to $20.00 and set an “outperform” rating for the company in a research report on Friday, February 28th. Finally, Truist Financial reduced their price objective on Iovance Biotherapeutics from $25.00 to $15.00 and set a “buy” rating for the company in a research report on Monday, March 3rd. One analyst has rated the stock with a sell rating, one has issued a hold rating and eight have issued a buy rating to the stock. According to MarketBeat, the stock currently has a consensus rating of “Moderate Buy” and a consensus target price of $18.22.

Iovance Biotherapeutics Trading Down 1.4 %

NASDAQ IOVA opened at $3.56 on Wednesday. The company has a market cap of $1.17 billion, a PE ratio of -2.39 and a beta of 1.05. Iovance Biotherapeutics, Inc. has a 12 month low of $2.70 and a 12 month high of $14.23. The stock has a 50 day moving average of $3.65 and a 200-day moving average of $6.47.

Iovance Biotherapeutics (NASDAQ:IOVA) last released its quarterly earnings data on Thursday, February 27th. The biotechnology company reported ($0.26) EPS for the quarter, hitting analysts’ consensus estimates of ($0.26). The firm had revenue of $73.69 million during the quarter, compared to analysts’ expectations of $72.17 million. Iovance Biotherapeutics had a negative net margin of 451.25% and a negative return on equity of 58.43%. As a group, sell-side analysts predict that Iovance Biotherapeutics, Inc. will post -1.24 EPS for the current fiscal year.

Iovance Biotherapeutics Company Profile

Iovance Biotherapeutics, Inc, a commercial-stage biotechnology company, develops and commercializes cell therapies using autologous tumor infiltrating lymphocyte for the treatment of metastatic melanoma and other solid tumor cancers in the United States. The company offers Amtagvi, a tumor-derived autologous T cell immunotherapy used to treat adult patients with unresectable or metastatic melanoma; and Proleukin, an interleukin-2 product for the treatment of patients with metastatic renal cell carcinoma.